Product Description
Butenafine is a new antifungal agent with primary fungicidal activity against dermatophytes such as Trichophyton mentagrophytes, Microsporum canis and Trichophyton rubrum which cause tinea infections. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9530545/)
Mechanisms of Action: SQE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Brazil | Canada | Chile | Ecuador | Egypt | India | Ireland | Israel | Korea | Mexico | Peru | Portugal | Saudi Arabia | Sweden | Taiwan | Turkey | United Arab Emirates | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|